← Back to Search

Monoclonal Antibodies

ADG20 for COVID-19 (EVADE Trial)

Phase 2 & 3
Waitlist Available
Research Sponsored by Adagio Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through 14 months
Awards & highlights

EVADE Trial Summary

This trial will test if ADG20 is safe and effective in preventing COVID-19 infection.

Eligible Conditions
  • COVID-19
  • Coronavirus

EVADE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through 14 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through 14 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of solicited injection site reactions
Incidence of treatment emergent adverse events
Secondary outcome measures
Assessment of PK Parameter: Area under the curve for ADG20
Assessment of PK Parameter: Clearance of ADG20
Assessment of PK Parameter: Cmax for ADG20
+20 more

EVADE Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ADG20Experimental Treatment1 Intervention
Participants will be dosed on Day 1 with ADG20 IM
Group II: PlaceboPlacebo Group1 Intervention
Participants will be dosed on Day 1 with placebo IM

Find a Location

Who is running the clinical trial?

Adagio Therapeutics, Inc.Lead Sponsor
1 Previous Clinical Trials
399 Total Patients Enrolled
1 Trials studying COVID-19
399 Patients Enrolled for COVID-19
Invivyd, Inc.Lead Sponsor
4 Previous Clinical Trials
1,219 Total Patients Enrolled
4 Trials studying COVID-19
1,219 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the defined goals for this clinical trial?

"The main goal of this clinical trial, as stated by the sponsor Adagio Therapeutics, Inc., is to measure the rate of treatment emergent adverse events over a 4 day period. Additionally, this study will secondary outcomes including viral load and SARS-CoV-2 titer in both the PEP and Prep populations."

Answered by AI

Is this clinical trial commonly available to patients in Canada?

"To limit the amount of travel required from participants, this trial is enrolling at 61 sites close to subjects. In addition to the locations in Houston, West Columbia and Beaumont, there are 58 other recruiting centres."

Answered by AI

Can people with specific medical conditions join this clinical trial?

"Unfortunately, this specific clinical trial is no longer recruiting patients. Though it was originally posted on April 27th, 2021 and last updated July 21st, 2022, there are over a thousand other trials that are still looking for participants."

Answered by AI

Who else is applying?

What state do they live in?
Other
Oregon
Texas
Florida
How old are they?
18 - 65
What site did they apply to?
Adagio Investigative Site
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Evaluation of ADG20 for the Prevention of COVID-19
2021. "Evaluation of ADG20 for the Prevention of COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04859517.
~1519 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top